Clinical trials
Metastatic Cervical Carcinoma clinical trials
Below are recruiting metastatic cervical carcinoma clinical trials, each written for real people, not researchers. We’re tracking 140 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05472948RecruitingPhase 2
Testing surufatinib plus immunotherapy with capecitabine for bowel cancer
This Phase 2 study tests a combination of anti-cancer drugs (surufatinib, immunotherapy, and capecitabine) to treat cancer that has spread to other parts of the body. It’s for people whose small intestine or appendix adenocarcinoma has progressed after earlier treatment, aiming to shrink tumors and improve control of the disease.
Guangzhou, GuangdongAges 18–70 - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT04318730RecruitingPhase 2
Study of immunotherapy plus targeted drug for adrenal cancer
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
Chengdu, SichuanAges 18 years+ - NCT05809869RecruitingPhase 2
Immunotherapy plus liver radiation for metastatic liver cancer
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
Hong KongAges 18 years+ - NCT05994170Recruiting
Lower radiation dose to tumor area for early nasopharyngeal cancer
This trial studies whether lowering the radiation dose to a smaller area around the tumor is safe and effective for people with newly diagnosed nasopharyngeal cancer that has not spread. It may reduce side effects while still curing the cancer.
Zhongshan, GuangdongAges 18–70 - NCT06321939Recruiting
Tracking EBV DNA in Blood for Nasopharyngeal Cancer
This trial studies whether tracking levels of Epstein-Barr virus DNA in your blood can help guide treatment for non-metastatic nasopharyngeal cancer. You would get standard radiation and maybe chemotherapy, with extra blood tests to see how the virus levels change.
Changsha, HunanAges 18 years+ - NCT06349980RecruitingPhase 2
Study of three drugs for liver cancer not yet treated
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
ShanghaiAges 18 years+ - NCT06629597RecruitingPhase 3
Study of YL201 for advanced nasopharyngeal cancer
This trial tests a new drug, YL201, in people with nasopharyngeal cancer that has come back or spread. It may be an option if you have already tried a PD-(L)1 inhibitor and at least two chemotherapy treatments.
Guangzhou, GuangdongAges 18–75 - NCT06805617RecruitingPhase 2
Ivonescimab for advanced salivary gland cancer
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06391190RecruitingPhase 1/Phase 2
Chemoradiation plus immunotherapy for advanced cervical cancer
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
ShanghaiAges 18–75 - NCT06529809RecruitingPhase 1/Phase 2
Accelerated brachytherapy and chemo for advanced cervical cancer
This trial tests a new way of delivering radiation therapy (brachytherapy) combined with chemotherapy for advanced cervical cancer. The goal is to see if a faster, more intense radiation schedule is safe and effective.
St Louis, MissouriAges 18 years+ - NCT06689540RecruitingPhase 1
MTS105 for advanced liver cancer with GPC3
This trial tests a new treatment called MTS105 for people with advanced liver cancer (HCC) that has not responded to standard therapies. It targets a protein called GPC3 found on some liver cancer cells, aiming to stop the cancer from growing.
BeijingAges 18 years+ - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Los Angeles, CaliforniaAges 18 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT07240610Recruiting
Radiation and immunotherapy for kidney cancer that has spread
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
Chūō, YamanashiAges 18 years+ - NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT06239220RecruitingPhase 2
Combination immunotherapy for advanced head and neck cancer
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
Boston, MassachusettsAges 18 years+ - NCT07213557RecruitingPhase 2
Simvastatin with immunotherapy for ARID1A-mutated stomach cancer
This trial tests whether adding the cholesterol drug simvastatin to standard immunotherapy and chemotherapy can help people with a specific type of gastroesophageal cancer (ARID1A mutated, HER2 negative). It is for patients who have not had prior treatment for advanced disease.
Naples, ItaliaAges 18 years+ - NCT06472713RecruitingPhase 2
Liposomal mitoxantrone with immunotherapy for advanced nasopharyngeal cancer
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Zhuhai, GuangdongAges 18–70 - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Orlando, FloridaAges 18 years+ - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70
Hear when a new Metastatic Cervical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cervical carcinoma?
- Yes. Clin2 currently lists 140 recruiting metastatic cervical carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cervical carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cervical carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.